Antiangiogenic agents: New therapeutic standards for metastatic renal cancer;Les anti-angiogéniques: de nouveaux standards thérapeutiques dans le cancer du rein métastatique

Progres en Urologie

Volumn 18, Issue SUPPL.4, 2008, Pages

  Cornu, J N ^a   Roupret M ^a   Bensalah, K ^b   Oudard, S ^c   Patard, J J ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Bevacizumab; Receptor tyrosine kinase inhibitor; Renal cell carcinoma; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ANGIOGENESIS INHIBITOR; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; SORAFENIB; SUNITINIB;

ARTICLE; HUMAN; KIDNEY TUMOR; METASTASIS; PATHOLOGY;

ANGIOGENESIS INHIBITORS; BENZENESULFONATES; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PYRIDINES; PYRROLES;

EID: 50849100478     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(08)73665-0     Document Type: Article

References (33)

1. Dreicer R. Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects. Clin Genitourin Cancer 5 Suppl 1 (2006) S19-23
2. Henriksson R., Nilsson S., Colleen S., Wersall P., Helsing M., Zimmerman R., et al. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer 77 (1998) 1311-1317
3. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma.Groupe Français d'Immunotherapie. N Engl J Med 338 (1998) 1272-1278
4. Stein M.N., and Flaherty K.T. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 13 (2007) 3765-3770
5. Bracarda S., Caserta C., Sordini L., Rossi M., Hamzay A., and Crino L. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Ann Oncol 18 Suppl 6 (2007) vi22-vi25
6. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12 (2006) 7271-7278
7. Gore M.E. Temsirolimus in the treatment of advanced renal cell carcinoma. Ann Oncol 18 Suppl 9 (2007) ix87-ix88
8. Ravaud A. New challenges in kidney cancer therapy: bevacizumab. Ann Oncol 18 Suppl 9 (2007) ix89
9. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
10. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
11. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
12. Shuin T., Kondo K., Torigoe S., Kishida T., Kubota Y., Hosaka M., et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54 (1994) 2852-2855
13. Blankenship C., Naglich J.G., Whaley J.M., Seizinger B., and Kley N. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18 (1999) 1529-1535
14. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275 (2000) 25733-25741
15. Fergelot P., Rioux-Leclercq N., and Patard J.J. Voies moléculaires de l'angiogenèse tumorale et nouvelles approches thérapeutiques ciblées dans le cancer du rein. Prog Urol 15 (2005) 1021-1029
16. Zimmer M., Doucette D., Siddiqui N., and Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2 (2004) 89-95
17. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
18. Sun L., Liang C., Shirazian S., Zhou Y., Miller T., Cui J., et al. Discovery of 5- [5-fluoro-2-oxo-1,2- dihydroindol- (3Z) -ylidenemethyl] -2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46 (2003) 1116-1119
19. Rosenberg JE. Sunitinib therapy for patients with metastatic renal cell carcinoma: updated results of two phase II trials and prognostic factor analysis for survival. Proc Am Soc Clin Oncol 2007:ASCO annual meeting, Abstract N °5095.
20. Motzer RJ. Sunitinib versus interferon-alpha as first-line treatment of metastatic renal cell carcinoma:updated results and analysis of prognostic factors. Proc Am Soc Clin Oncol 2007: ASCO annual meeting, Abstract N °5024.
21. Motzer R.J., Hutson T.E., Tomcsak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
22. Wilhelm S. Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 8 (2002) 2255-2257
23. Wilhelm S.M., Carter C., Tang L., Wilkie D., Mcnabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
24. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., Tewes M., et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
25. Ratain M.J., Flaherty K.T., Stadler W.M., O'Dwyer P., Kaye S., Xiong H., et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol 22 (2004) 4501 (Meeting Abstracts)
26. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
27. Szczylik C. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma:final results. Proc Am Soc Clin Oncol, 2007: ASCO annual meeting, Abstract N °5025.
28. Atkins M.B., Hidalgo M., Stadler R W.M., Logan T.F., Dutcher J.P., Hudes G.R., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
29. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
30. Raymond E., Alexandre J., Faivre S., Vera K., Materman E., Boni J., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336-2347
31. Bukowski R.M., Kabbinavar F.F., Figlin R.A., Flaherty K., Srinivas S., Vaishampayan U., et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25 (2007) 4536-4541
32. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (2002) 673-682
33. Escudier B. Traitement du cancer du rein: les résultats clinique du Nexavar. Prog Urol 17 (2007) 150-153